# Lead4Life PPP 2026 – Lead-212 Production & Enabling Technologies

**Funder:** KWF
**Budget:** €0.5M–€2M per project (total programme €5M)
**Deadline:** 22 September 2026 (12:00 noon; full-proposal phase opened 5 May 2026)
**Duration:** Up to 4 years
**Consortium:** Required — public-private partnership consortium; Consortium Agreement between all participants is mandatory
**Application:** 2-stage: matchmaking phase → full-proposal submission via KWF GMS
**TRL:** 1-7
**Frequency:** One-off
**Eligible countries:** NL
**Official call:** https://www.kwf.nl/en/forresearchers/funding/lead4life
**Last verified:** 1 July 2026

## Eligibility & scope

Health~Holland PPP call for projects on lead-212 (Pb-212) production/supply chain or enabling technologies for clinical introduction. Requires active private-party participation (PPP), a signed Consortium Agreement, and compliance with Health~Holland PPP subsidy guidelines. Private party must not be an undertaking in difficulty (RVO declaration required). Proposals must be submitted in Dutch (Dutch Summary reviewed by Patient Advisory Committee PACO).

## Summary

The KWF Lead4Life PPP 2026 call funds public-private partnerships pursuing lead-212 radiopharmaceutical research for cancer treatment, with grants of €0.5-€2 million per project (total programme budget €5 million). Proposals must address one of two pillars: lead-212 production and supply-chain development, or enabling technologies for clinical introduction. Dutch research institutions partnered with private-sector organizations must apply as consortia; the private partner must be financially viable and sign a mandatory Consortium Agreement.

## Who should apply

- Academic or hospital research teams in the Netherlands with radiopharmaceutical or nuclear medicine expertise
- Consortium-based applicants: at least one Dutch public research institution and one private-sector partner financially able to participate
- Projects targeting lead-212 production/supply chain or clinical-translation technologies for cancer therapy
- Teams willing to engage with the Patient Advisory Committee on the Dutch summary of their proposal

## Key dates

- Full-proposal deadline 22 September 2026 at 12:00 noon (submitted via KWF GMS)
- Two-stage process: matchmaking phase followed by full proposal submission
- Up to four-year project duration; funding decision expected end of February 2027

## Tips for applicants

- Register in the KWF GMS platform at least 6 weeks before the deadline if your institute is new to KWF; late registration will stall your submission.
- The Consortium Agreement is non-negotiable and mandatory; draft and sign it before proposal submission.
- Write your Dutch summary in genuinely plain language, the Patient Advisory Committee review focuses on clarity for non-specialists, not scientific depth.

## Frequently asked questions

### What is the budget range for the KWF Lead4Life PPP 2026 grant?

Individual projects can receive €0.5 million to €2 million; the total programme budget is €5 million.

### Do I need a private-sector partner to apply to Lead4Life PPP?

Yes, the call requires a public-private partnership consortium; your private-sector partner must provide an RVO declaration confirming financial viability.

### What research areas does the Lead4Life PPP 2026 call cover?

The call funds two pillars: lead-212 production and supply-chain development, and enabling technologies for clinical introduction of lead-212 cancer therapies.

### When is the deadline for the KWF Lead4Life PPP 2026?

The full-proposal deadline is 22 September 2026 at 12:00 noon, submitted via the KWF GMS system.

### Is the Lead4Life PPP 2026 call recurring?

No, this is a one-off call run by Health~Holland as a structured PPP initiative.

---

Source: [The Great Grantsby](https://grantsby.eu/grants/kwf-lead4life-ppp-2026-lead-212-production-enabling-te) — EU grant monitoring for academic researchers. Always verify details on the funder's website before applying.